Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$177.74K-$177.74KderivedN/M vs Q4 2020 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$460,482N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
Operating Cash Flowderived-$186,852N/M ended Dec 31, 2021 · filed Mar 15, 2022 · 74 d after period end